Utah Medicaid and GLP-1 coverage

Utah ended it on a dated bulletin that names the drugs: "Effective June 30, 2026, Utah Medicaid fee-for-service (FFS) will no longer cover GLP-1 agonists, including Wegovy, Saxenda, and Zepbound for weight loss for FFS members." The same item keeps the other doors open — Utah "will continue to cover GLP-1 agonists for other FDA-approved indications, including major adverse cardiovascular events, metabolic dysfunction-associated steatohepatitis, and severe obstructive sleep apnea."

Utah Department of Health and Human Services, Medicaid Information Bulletin, May 2026 (item 26-45), effective June 2026 · source

It had begun eleven months earlier, on the same kind of document. "Effective July 1, 2025, select GLP-1 agonists (including Wegovy, Saxenda, and Zepbound) will be covered for fee-for-service members. The coverage criteria is for children that have BMI ≥ 95th percentile, and for adults present with a diagnosis of obesity with BMI ≥ 30 kg/m2, or overweight with BMI 27-29.9 kg/m2 and at least one weight-related comorbidity." That bulletin also drew the line the state never moved: "These medications are not covered in ACO enrolled populations." Utah runs most of its Medicaid through accountable care organizations, so the pilot never reached most members.

Utah Department of Health and Human Services, Medicaid Information Bulletin, July 2025 (item 25-54), effective July 2025 · source

The state told prescribers it was temporary, on the form itself. Among the reauthorization questions: "Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?" The authorization-duration table carries the same date — obesity approvals run "Up to and no later than 6/30/2026" for reauthorizations, with a footnote that "Coverage for weight-loss is part of a pilot program and may not continue past 6/30/2026". The form's own footer reads "Last Updated 6-1-26".

Utah Medicaid, Pharmacy Prior Authorization Request Form — GLP-1 Medications for Weight-related Comorbidities, effective June 2026 · source

By the end, plain obesity had no way in. The form routes a request for "Saxenda, Wegovy, or Zepbound, for patients with obesity who do not otherwise fit the categories above" straight to the reauthorization section, and that section asks whether the patient already held an approval for weight loss during the pilot year. A patient without one had no initial-approval path to reach.

Utah Medicaid, Pharmacy Prior Authorization Request Form — GLP-1 Medications for Weight-related Comorbidities, effective June 2026 · source

The three surviving routes each carry their own evidence bar, and two of them require a specialist. Wegovy for cardiovascular risk asks whether the patient has "a Body Mass Index (BMI) of ≥ 27 kg/m2" together with a qualifying prior event. Zepbound for sleep apnea asks for a BMI "greater than or equal to 30 kg/m2" plus "a diagnosis of moderate-to severe obstructive sleep apnea (OSA) confirmed by an apnea-hypopnea index (AHI) of 15 or higher as determined by an in-lab attended sleep study OR polysomnography (PSG)", and adherence to positive airway pressure therapy of "at least 70% adherence". Wegovy for liver disease asks for stage F2 to F3 fibrosis. Across all routes the form asks for a calorie-restricted diet and an exercise program, no personal or family history of medullary thyroid carcinoma or MEN 2, and no concurrent GLP-1, GIP or DPP-4 therapy.

Utah Medicaid, Pharmacy Prior Authorization Request Form — GLP-1 Medications for Weight-related Comorbidities, effective June 2026 · source

The drug list now states the class rule in one line. Under its GLP-1 Agonists heading the preferred drug list says these drugs "are only covered for type 2 diabetes mellitus" and that "All GLP-1 Agonists are mutually exclusive with each other. Only one GLP-1 per month may be covered." Saxenda, Wegovy and Zepbound appear nowhere on a drug line of that list — they survive only as an entry in its index of prior authorization forms.

Utah Medicaid, Fee-for-Service Preferred Drug List, effective September 1, 2026, effective September 2026 · source

Utah does not carve the pharmacy benefit back to the state for these drugs, and its own list is what shows it. The provider manual sets out the classes "carved out from MCE coverage and are part of the FFS Medicaid benefit" and names ten: alcohol use disorder treatments, anti-anxiety, anticonvulsant, antidepressant, antipsychotic and attention deficit hyperactivity disorder drugs, hemophilia drugs, opioid use disorder treatments, transplant immunosuppressive drugs, and ultra-high-cost drugs at or above one million dollars per dose. GLP-1s and weight-loss agents are not among them, so for a member in a managed care plan the plan's own rules apply and the manual directs the reader to contact it.

Utah Medicaid Provider Manual, Pharmacy Services, Division of Integrated Healthcare, effective May 2026 · source